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INTRODUCTION
In humans, hair's main purpose revolves around its 
profound role in social interactions. Oliver Herford said 
“A hair in the head is worth two in the brush”. Given 
their prominence in daily dermatologic practice, hardly 
any dermatologist can escape having to manage patients 
with hair growth disorders.
ALOPECIA AREATA (Abbreviation : AA) is a chronic, 
organ-specific autoimmune disease, probably mediated by 
autoreactive T cells, which affects hair follicles and 
sometimes the nails. Although not life threatening, the 
cosmetic  disfigurement  that  leads  on  to  significant 
psychological  and  emotional  distress  supports  a 
multibillion-dollar effort to reverse this condition. 
Though  various  modalities  are  available  for  the 
treatment of alopecia areata, assessment of the efficacy 
of a treatment must be considered with care because the 
condition  is  highly  unpredictable  in  presentation, 
evolution, and response to treatment. Little data exist 
regarding the natural evolution of the condition. Hence 
with this in mind the following study was carried out to 
see  the  treatment  response  for  various  modalities  and 
chances  of  spontaneous  resolution  for  this  benign 
condition. 
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REVIEW OF LITERATURE
INTRODUCTION
Hair is a cutaneous appendage typical of mammalian skin1. It has 
lost its functional value in humans except probably over the scalp. With 
the exception of the palms, soles, dorsa of terminal phalanges of digits1, 
glans  penis  and  mucocutaneous  junctions,  the  entire  skin  surface  is 
populated  by  hair  follicles.  The  follicular  density  (number  of  hair 
follicles/cm2) decreases with age. 
HAIR CYCLE
Hair  grows in  cycles  of  various  phases:2 anagen is  the  growth 
phase( 2 – 10 yrs);  catagen is the involuting or regressing phase(1 - 3 
wks);  followed by  telogen,  the resting or  quiescent  phase (3 months). 
Prior  to  the  start  of  cycling  is  a  phase  of  follicular  morphogenesis 
(formation of the follicle). There is also a shedding phase, or exogen, that 
is independent of anagen and telogen in which one of several hairs that 
might arise from a single follicle exits. Normally up to 90% of the hair 
follicles are in anagen phase while, 10–14% are in telogen and 1–2% in 
catagen. The cycle's length varies on different parts of the body. Growth 
cycles are controlled by a chemical signal like epidermal growth factor.
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ALOPECIA AREATA (AA) – DEFINITION
Alopecia Areata is defined as a sudden or 
gradual complete loss of hair in sharply defined 
round  or  oval  patches  without  accompanying 
atrophy or inflammation resulting in non scarring 
smooth patch of baldness. Hippocrates first used 
the term alopecia (literally translated as “Fox’s 
disease”). Alopecia areata was first described by 
Cornelius celsus in 30AD & Sauvages used the term 
alopecia areata.
SYNONYMS3
Alopecia  Celsi,  Porrigo  Decalvans,  Alopecia  Circumscripta, 
Cazenave's  Vitiligo,  Celsus'  Vitiligo,  Vitiligo  capitis,  Alopecia 
cicatrisata, Fox’s disease, Jonston's Alopecia, Area celsi , Area tonstonii, 
Pelade of the French, Tinea decalvans & Ophiasis of the Greek.
SUBTERMS OF ALOPECIA AREATA4
Alopecia areata : Most commonly used term covering all  forms 
of the disease.
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Alopecia partialis: Name given to specific patchy hair loss.
Alopecia Totalis: Complete loss of terminal hair 
on the scalp.
Alopecia  Universalis: Total loss of all terminal 
hair on the scalp and body.
Oophiasis  : Band-like pattern of hair loss at 
the periphery of the scalp. Usually affecting the 
occipital  and  temporal  region.  Oophiasis  comes 
from the latin word ‘Snake’ and in Greek means 
serpent due to the winding turban or snake like 
pattern  of  hair  loss  on  the  periphery  of  the 
scalp.
Sisaipho  AA: It is defined as entire loss of 
scalp  hair  except  for  a  narrow  ring  of  hair 
around  the  periphery.  This  term  is  used  by  a 
clinical group in Seville, Spain (Munoz1996)
Alopecia  Areata  Barbae:  Alopecia affecting  the 
hair of the beard region.
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Reticular  Alopecia  Areata:  Hair  loss  occurs  in 
irregular patterns in a net like fashion. In the 
scalp,  there  are  regions  of  hair  loss 
interspersed with areas of normal hair growth.
Diffuse type of  Alopecia Areata: In this case, there 
is a premature cessation of anagen growth, which 
causes partial hair loss throughout the scalp. No 
distinct patches are evident.
Perinevoid Alopecia Areata: A very rare form of AA 
where patches of hair loss occurs around naevi.
Triangular AA: Another very rare form where the 
hair loss presents in a triangular shape.
AETIOLOGY
At any given time 0.2% have alopecia areata 
and approximately 1.7% experience an episode of a 
AA during their lifetime. Various theories have 
been put forth but these couldn’t stand the test 
of  time.  They  are  the  parasitic  theory 
(infectious etiology), trophoneurotic theory (AA 
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was  produced  in  cats  following  denervation 
associated  with  stress),  genetic,  trauma,  tick 
bites,  immunologic,  focal  sepsis  and  endocrine 
theory (associated with thyroid disorders)5,6.
The etiopathogenesis of AA will be discussed 
under the following headings:
• Genetic factors
• Immunological factors
• Atopy 
• Stress
• Infections
GENETIC FACTORS
Many factors favor a genetic predisposition for 
alopecia areata. The frequency of positive family 
history for alopecia areata in affected patients 
has  been  estimated  to  be  10-20%7.  The  mode  of 
inheritance  is  ought  to  be  autosomal  dominant 
with variable penetrance. One study showed that 
the concordance rate of 55% for alopecia amongst 
monozygotic twins. Two studies demonstrated that 
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human leukocyte antigen DQ3 (DQB1*03) was found 
in  more  than  80%  of  patients  with  alopecia 
areata, which suggests that it can be a marker 
for  general  susceptibility  to  alopecia  areata. 
The  studies  also  found  that  human  leukocyte 
antigen  DQ7  (DQB1*0301)  and  human  leukocyte 
antigen  DR4  (DRB1*0401)  were  present 
significantly  more  in  patients  with  alopecia 
totalis and alopecia universalis8,9,10   
Other possible associations that were found are 
HLA – A1, HLA  –B62, HLA – DR4, HLA DQ – 1, HLA –
DQ3,  HLA-  DR11.  Juvenile  onset  and  severe 
involvement were related with CW7 and DR1. HLA –
DR5 is linked to early onset form of AA and more 
extensive hair loss. HLA DR16 was significantly 
less commonly found in patients and this allele 
probably has a protective role for AA11,12.  Another 
gene, the interleukin 1 receptor antagonist gene, 
may correlate with disease severity. TNF – alpha 
gene polymorphism has been found to be associated 
with autoimmune/ inflammatory diseases including 
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Systemic  lupus  erythematosus,  Rheumatoid 
arthritis,  Dermatitis  herpetiformis  and  celiac 
diseases. Finally, there is upto 8.8% increased 
frequency of AA in patients with Down’s syndrome. 
The increased frequency of down’s syndrome and 
polyglandular syndrome type 1 is due to mutation 
of autoimmune regulator gene on chromosome 21.
IMMUNOLOGICAL FACTORS
Much  evidence  supports  the  hypothesis  that 
alopecia  areata  is  an  autoimmune  condition13. 
Increased incidence of circulating organ-specific 
antibodies  against  thyroid,  gastric  parietal 
cell, adrenal tissue, smooth muscle, testes and 
the  ovaries  have  been  reported14,15. A 
statistically significant association between AA 
and  hashimoto’s  thyroiditis,  addison’s  disease, 
and pernicious anemia has been reported16. Other 
autoimmune diseases that have occurred with AA 
include  vitiligo  (4%),  lichen  planus,  morphea, 
lichen  sclerosus  et  atrophicus,  pemphigus 
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foliaceus,  lupus  erythematosus,  Sjogren’s 
syndrome, ulcerative colitis, myasthenia gravis, 
autoimmune  hemolytic  anemia,  diabetes  mellitus, 
autoimmune  testicular  and  ovarian  disease  and 
chronic  mucocutaneous  candidiasis  with 
endocrinopathy17
HUMORAL IMMUNITY18
Antibodies directed to multiple hair follicle structures have been 
found with increased frequency in alopecia areata patients compared with 
control subjects by Toban et al using immunofluorescence. The outer root 
sheath is the structure targeted most frequently, followed by the inner root 
sheath,  the  matrix,  and the hair  shaft.  Anti  hair  follicle  antigen (IgG) 
expressed in alopecia areata is also expressed by hair follicle melanocyte 
and keratinocytes in vitro supporting that  melanocyte and keratinocyte 
are also possibly targeted in AA.
CELL MEDIATED IMMUNITY
The following studies supports the cell- mediated immunity theory. 
Messenger et al found that hair bulb keratinocytes aberrantly expressed 
HLA-DR antigen, indicating immunological cell injury. Total numbers of 
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circulating  T  lymphocytes  have  been  reported  at  both  decreased  and 
normal levels. Studies have shown that hair regrows when affected scalp 
is  transplanted  onto  SCID (severe  combined  immunodeficiency)  mice 
that  are  devoid  of  immune  cells19.  Response  of  AA  to  a  variety  of 
immunomodulators  such  as  cyclosporine,  Isoprinosine,  thymopentin, 
contact sensitizers,  PUVA, and steroids also supports the immunologic 
hypothesis20,21. Target cells implicated in immune response in AA have 
been  identified  as  keratinocytes,  melanocytes,  and  follicular  papillary 
fibrocytes.  Loss  of  “immune  privilege”  has  been  hypothesized  to  be 
causative of AA. 
CYTOKINES
Recent studies have suggested that cytokines play a critical role in 
the pathophysiology of alopecia areata. Interleukin 1 and tumor necrosis 
factor were shown to be potent inhibitors of hair growth in vitro. Serum 
levels of cytokines, including interferon γ (IFN-γ), tumor necrosis factor 
α,  interleukin  1α  (IL-1α),  IL-2,  IL-4,  and  IL-6,  were  measured  using 
radioimmunoassay or enzyme-linked immunosorbent assay techniques in 
patients  with  the  localized  form  and  the  extensive  form  (alopecia 
universalis).  The  serum  levels  of  IL-1α  and  IL-4  were  significantly 
elevated in patients with the localized form. In contrast, the serum levels 
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of  IFN-γ  and  IL-2  were  significantly  elevated  in  patients  with  the 
extensive  form.  These  results  indicate  that  immune  responses  in  the 
localized form and the extensive form of alopecia areata are regulated by 
Th2 cytokines and Th1 cytokines, respectively22.
ATOPY
The association  between a  history of  atopy and AA is  not  well 
established.  A  study  analysis  revealed  that  a  history  of  atopy  and 
autoimmune disease was associated with an increased risk of AA and that 
the results were consistent  for both the severe subtype of AA and the 
localized subtype (ie,  AA persistent)23. In Ikeda’s classification  the 2nd 
type is called atopic type and accounts for 10% of AA patients.
STRESS  
Psychosocial stress has been reported to play a role in the onset 
and/or  exacerbation  of  alopecia  areata  via  psychoneuroimmunological 
pathways24. A  study  analysis  revealed  that  patients  whose  alopecia  is 
stress-reactive may suffer from depressive illness, a potentially important 
consideration in the overall management of such patients25.
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INFECTIONS
Alopecia areata was believed to possibly have an infectious origin, 
but no microbial agent has been isolated consistently in these patients. 
Many  efforts  have  been  made  to  isolate  cytomegalovirus,  but  most 
studies have been negative.13  Focal sepsis particularly dental disease has 
been reported as precipitating factor for AA26.
INNERVATION AND VASCULATURE13
Another  area  of  interest  concerns  the  fact  that  patients  with 
alopecia areata occasionally report itching or pain on affected areas raises 
the possibility of alterations in the peripheral nervous system. Circulating 
levels of the neuropeptide calcitonin gene-related peptide (CGRP) were 
decreased in patients with alopecia areata. CGRP has multiple effects on 
the immune system, including chemotaxis and inhibition of Langerhans 
cell  antigen  presentation  and  inhibition  of  mitogen-stimulated  T-
lymphocyte  proliferation.  CGRP  also  increases  vasodilatation  and 
endothelial  proliferation.  More studies are needed to shed light  on the 
significance of these findings.
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HISTOPATHOLOGY27,28
The  diagnostic  pathologic  feature  is 
peribulbar  lymphocytic  inflammation  (swarm  of 
bees) affecting anagen follicles or follicles in 
early catagen. The inflammatory assault on anagen 
follicles  induces  a  premature  conversion  to 
catagen. Consequently, the number of catagen and 
telogen follicles found to be approaching 100%. 
Follicles may enter a persistent phase of telogen 
in which the hair shaft has already been shed, 
manifested  by  the  telogen  germinal  unit.  As 
follicles enter catagen, peribulbar inflammation 
frequently  disappears,  but  the  lymphocytic 
infiltrate in late catagen may be present around 
the epithelial remnant of the receding follicle, 
and  also  within  and  surrounding  the  collapsed 
follicular sheaths. Telogen hairs show little to 
no  perifollicular  inflammation.  Lymphocytes  may 
also  be  seen  sparsely  infiltrating  the  matrix 
epithelium of anagen follicles, inducing damage 
to the matrical cells that includes intra- and 
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intercellular  edema,  cellular  necrosis,  and 
microvesicle formation. 
As a result of injury to bulbar melanocytes 
and  keratinocytes,  pigment  casts,  which  are 
clumps of melanin pigment, may be found within 
the dermal papilla, the sheath of miniaturizing 
or  regressing  follicles,  or  in  the  follicular 
epithelium.  Abnormal  follicles  called  nanogen 
hairs are a distinctive finding in long-standing 
cases. As telogen follicles re-enter anagen, the 
follicles  miniaturize  and  are  situated  more 
superficially, with their bulbs situated in the 
mid  to  lower  dermis.  Miniaturization  and 
conversion  to  catagen  and  telogen  leave  many 
collapsed fibrous root sheaths in the subcutis. 
Whiting  found  that  transversely  sectioned 
scalp biopsies showed the diagnostic features of 
alopecia  areata  more  often  than  vertically 
sectioned  biopsies.  He  emphasized  the  use  of 
follicular counts to aid in the diagnosis of AA 
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when  the  characteristic  peribulbar  inflammation 
is  missing.  Eosinophils  have  been  demonstrated 
around the bulb and within fibrous tracts. Some 
plasma  cells  may  also  be  present28.  In  long-
standing AA, the inflammatory infiltrates appear 
to diminish.
HISTOPATHOLOGICAL DIFFERENTIAL DIAGNOSIS29
Alopecia syphilitica may include lymphocytes 
situated near the isthmus, the presence of plasma 
cells,  an  endothelial  reaction,  interface 
dermatitis, or neutrophils in the stratum corneum 
closely  mimic  active  AA.  Androgenic  alopecia 
shows  diminution  of  follicular  size,  dermal 
infiltrates that are present in this condition 
are usually superficial, perivascular, and peri-
infundibular. In telogen effluvium normal number 
of  hair  follicles  with  no  miniaturization  of 
follicles and a slight decrease in the anagen to 
the telogen ratio may be noted30
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ELECTRON MICROSCOPIC CHANGES AND 
IMMUNOHISTOCHEMISTRY 30,31,32
Electron  microscopic  changes  in  the 
perivascular zone of both unaffected and affected 
skin  showed  rich  infiltrate  of  CD4+  cells  and 
CD1a+ cells,  in the progressive phase of AA. In 
the stabilized phase the infiltrate was scanty, 
both in unaffected and affected skin and limited 
to the peribulbar area.             
Receptors  of  adhesion  molecules  (ICAM-2, 
ELAM-I, LFA-1) were strongly expressed, mainly at 
the microvascular level in both unaffected and 
affected skin in the progressive phase, but were 
only  weakly  or  not  at  all  expressed  in  the 
stabilized  phase,  these  adhesion  molecules  can 
mediate  the  adherence  of  leucocytes  to 
endothelial  cells  and  their  subsequent 
trafficking into the dermis which probably is one 
of  the  first  immunologic  events.  Ilaria 
ghersetich et al. concluded that an immunologic 
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process,  apparently  carried  out  by  CD4+ 
lymphocytes  and  by  dendritic  CD1a+  and  CD36+ 
cells, may play a key role at least in the early 
phase  of  the  disease  involving  primarily 
microvessels and later on the bulbar area.
CLINICAL FEATURES 4,33
Alopecia  areata  is  responsible  for  0.7-  3%  of  patients  seen  by 
dermatologists. All  races  are  affected,  one  study  showed  equal  sex 
incidence34.   AA can occur at any age from birth to the late decades of 
life.  Congenital  cases  have  been  reported.  Peak  incidence  appears  to 
occur from age 15-29 years. 
Alopecia  areata  most  often  is  asymptomatic,  but  some  patients 
(14%) experience a burning sensation or pruritus in the affected area. The 
characteristic lesion of AA is commonly a round or oval; totally bald, 
smooth patch. The condition usually is localized when it first  appears. 
Alopecia areata most often affects the scalp however, it can affect any 
hair-bearing area. More than one area can be affected at once.
The following forms are commonly seen
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• Patchy AA  – Most  common  type,  characterised  by round or 
oval patches of hair loss.
• Reticular AA – Reticulated pattern of patchy hair loss.
• Oophiasis band like AA – Hair loss in the parietal temporal – 
occipital scalp.
• Oophiasis inversus ( Sisapho )- a rare band like pattern of hair 
loss in the frontal parietotemporal scalp ( the exact opposite of 
oophiasis).
• Diffuse AA – A diffuse decrease in hair density over the entire 
scalp.
By the extent of involvement, the following types may be seen.
• Alopecia areata – Partial loss of scalp hair
• Alopecia totalis – 100% loss of scalp hair
• Alopecia universalis – 100% loss of hair on scalp and body.
Ikedas’ has categorized AA into 4 types31 as follows
• Type  1 –  The  common  type.  Accounts  for  83% of  patients, 
mainly between age of 20 and 40 yrs.  The condition usually 
lasts less than 3 yrs. Individual patches tend to regrow in less 
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than  6  months  and  only  about  6% of  patients  progressed  to 
alopecia totalis.
• Type 2 – The atopic type. Accounts for 10% of patients. The 
onset  is  usually  in  childhood and the  disease  runs  a  lengthy 
course  were  individual  patches  tends  to  persist  a  year  and 
alopecia totalis developed in 75%.
• Type  3 –  The  prehypertensive  type:  Accounts  for  4%  of 
patients,  occurs  mainly  in  young  adults.  The  disease  runs  a 
rapid course with an alopecia totalis in 39% of patients.
• Type 4 – The combined type (5%) occurred mainly in patients 
over 40 years of age. The disease runs a prolonged course with 
alopecia totalis developing in about 10% of patients only.
A frequent feature of an AA patch is “exclamation mark” that may 
be present at its margin3. The presence of exclamation point hairs /easily 
extractable  short  broken hairs  (ie.  hairs  tapered near  proximal  end)  is 
pathognomonic but is not always found. A positive result from the hair 
pull test at the periphery of a patch usually indicates that the disease is 
active, and further hair loss can be expected.
25
A hand lens shows that at the margin, the free ends are splayed, 
giving a frayed appearance.  Even the apparently normal  terminal  hair, 
found within the patches, may show one or more constrictions in their 
shaft. Shuster has described the coudability sign (to differentiate diffuse 
AA from other diffuse alopecia), in AA, a normal looking hair kinks at 
angle of 45 degree when forced inwards, the kink being situated 5 – 10 
mms above the surface35.
COURSE OF ALOPECIA AREATA
AA  runs  a  highly  unpredictable  course.  The  initial  patch  may 
regrow within  a  few  months,  or  further  patches  may  appear  after  an 
interval of  3 to 6 weeks and further patches may appear in a cyclical 
fashion at varying intervals. A succession of discrete patches may rapidly 
become confluent by the diffuse loss of remaining hair. Diffuse hair loss 
also may occur over a part or whole of the scalp without the development 
of bald patches. Patients with sudden diffuse onset of AA would appear 
to “go white” over the course of a few days. Re- growth is often at first, 
fine and unpigmented but usually the hair gradually resume its normal 
caliber and colour. Persistent depigmented hair regrowth from the site of 
AA has also been reported36..
26
ASSOCIATED CLINICAL SIGNS4,13,30
NAIL CHANGES
One  of  the  clinical  features  of  alopecia  areata  is  aberrant  nail 
formation. This feature is found in almost 10% to 66% of people affected 
by this  disease.  Nail  changes  usually  coincide with hair  loss  but  may 
occur earlier or later than the hair shedding, by months or years. Finger 
nails  are  commonly  involved.  The  commonest  nail  aberration  is  nail 
pitting – superficial,  uniform minute pits arranged regularly along and 
across the nail giving a “Scotch Plaid” effect or coalescing into ripples. 
The disease causes irregular keratinization on the nails. These irregular 
keratins fall off from the nails leaving behind depressions or pits.
Other  changes  include  thinning  or  thickening,  onychorrhexis 
(brittle nails having vertical ridges, which sometimes split vertically and 
peel off),  onychomadesis (proximal part of the nail separates from the 
nail bed, leading on to shedding), onycholysis, koilonychia punctuate or 
transverse leuconychia and red spotted lunula. Some others speculate the 
possibility of “twenty nail dystrophy sine alopecia”
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HISTOLOGY OF NAIL CHANGES4,13,30
Both, light and electron microscopy show that the disease affects 
the upper or the proximal part of the nail plate in a major way, the lower 
or distal part in a minor way while the subungal or the nail bed is largely 
spared which suggests a deep disorder of the matrix keratinization.
EYE CHANGES37,38
Keratoconus, cataract are the most common eye changes reported 
in association with AA. Other reported eye anomalies include Horner’s 
syndrome, ectopia of the pupil,  iris atrophy or tortuosity of the fundal 
vessels.
DIAGNOSIS
Diagnosis usually can be made on clinical grounds. Examination of 
hair from the margins reveal “exclamation mark hair”, coudability sign 
helps in the diagnosis. A scalp biopsy seldom is needed, histology can be 
used to corroborate the diagnosis.  Trichogram reveals a mixed telogen 
dystrophic  pattern.  Telogen  hair  predominates  in  slowly  progressive 
patches  and  dystrophic  anagen  hairs  form  the  majority  in  rapidly 
progressing  disease.  In  alopecia  areata,  dermoscopy  of  active  disease 
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shows yellow dots, dystrophic hairs, as well as cadaverized (black dots) 
and exclamation mark hairs. The presence of numerous yellow dots is a 
specific  feature of  alopecia areata,  occurring in 95% of patients  in all 
stages of the disease39,40. 
Complete  hemogram,  motion  examination,  ear,  nose,  throat  and 
dental examinations are done to rule out any foci of sepsis.  Potassium 
hydroxide wet mount of hair root is examined to rule out tinea capitis and 
serological  test  is  done to  rule  out  syphilis.  Random blood sugar  and 
serum levels of thyroid hormones may be of use and may be done in 
suspected cases1,30,37.
DIFFERENTIAL DIAGNOSIS1,30,37
AA has to be differentiated from the following conditions.
Trichotillomania -Alopecic  patches  have  broken  hairs  seen  at 
varying  levels;  no  inflammation  or  epidermal  change  occurs.  A scalp 
biopsy can be helpful if the diagnosis is difficult clinically.
Tinea  capitis -  The diagnosis  is suggested  by 
crusting, erythema rarely and interspersed areas 
of  broken  stubs  of  hair  and  scaling  with  dry 
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lustreless  hair  together  giving  appearance  of 
grey patch and black dot locally on the scalp. 
Hair root examination in KOH wet mount helps in 
ruling out the condition.
Telogen  effluvium -  believed  to  be  associated  with  high  fever, 
severe  emotional  stress,  sudden  starvation,  certain  medications  and 
predominantly consist of telogen hairs. Other conditions associated with 
diffuse alopecia ( to be ruled out in diffuse AA) include acrodermatitis 
enteropathica, arsenicism and thallium poisoning, though these conditions 
usually have systemic symptoms41.
Secondary  syphilis  -  It  is  a  moth  eaten  alopecia  with  positive 
serological test.
Androgenetic alopecia – Hair loss is patterned and 
usually is slowly progressive rather than acute.
Congenital triangular alopecia – characterized by a triangular area 
overlying the frontotemporal suture just inside the anterior hair line with 
its base directed forward which is completely bald or covered by sparse 
vellus hair42.
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Alopecia neoplastica - a rare form of alopecia, is associated most 
commonly with breast cancer; it may resemble localized alopecia areata, 
a biopsy usually clinches the diagnosis43,44 
Scarring  alopecia  and post  traumatic  alopecia: These can 
be differentiated by the absence of follicular 
ostia or some degree of atrophy. Systemic lupus 
erythematosus may also at times resemble alopecia 
areata.
PROGNOSIS 
Alopecia  areata  prognosis  will  vary  from 
person to person. The prognosis is good in case 
of common simple form of AA in which the hair 
loss is confined to the scalp and has got a high 
natural remission rate.
The  following  are  indicators  of  poor 
prognosis  -  Child  with  atopy,  patients  with 
Down’s  syndrome,  alopecia  totalis  or  alopecia 
universalis, involvement of more than 50% of the 
scalp, oophiasis and reticular pattern, bilateral 
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loss  of  eyebrow  and  eyelashes,  severe  nail 
changes  and  when  associated  with  autoimmune 
disorders.
TREATMENT1,37
Treatment  is  not  mandatory  because  the 
condition is benign, and spontaneous remissions 
and recurrences are common. Treatments used are 
believed  to  stimulate  hair  growth,  but  no 
evidence  indicates  they  can  influence  the 
ultimate  natural  course  of  alopecia  areata. 
Treatment  modalities  are  usually  considered 
according  to  the  extent  of  hair  loss  and  the 
patient's  age.  An  unpredictable  course  and 
heterogenity  of  the  disease  leads  to  varying 
results being obtained with the same therapy. The 
various modalities can be classified as follows,
1.Topical therapy
2.Systemic therapy
3.Others
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TOPICAL THERAPY includes
1. Immunosuppressants37,45 – corticosteroids: with or 
without  occlusion,  intralesional  steroids, 
nitrogen mustard.
2. Contact sensitizers – SADBE, DNCB, Diphencyprone
3. Irritants  – Anthralin, phenol, salicyclic acid, 
sulfur, oil of cade, cantharidin, croton oil, 
tretinoin
4. Photochemotherapy – topical PUVA, turban PUVA
5. Cryotherapy – liquid nitrogen
6. Laser  therapy – Excimer laser (308nm), pulsed 
infrared diode laser(904nm)
7. Other  topical  modalities –  topical  tacrolimus, 
imiquimod, topical minoxidil.
SYSTEMIC THERAPY
1. Immunosuppressants -  corticosteroids, 
cyclosporine
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2. Immunomodulators  –  Alefacept,  Isoprinosine 
(inosiplex), systemic psoralen etc.
3. Photochemotherapy – whole body PUVA
4. Miscellaneous – sulfasalazine, IV Ig
OTHERS
1. Psychotherapy –  hypnotherapy,  systematic 
desensitization
2. Supportive  therapy  –  Dermatography  (tattooing), 
wigs
3. Investigational  therapy –  Recombinant  human  bone 
morphogenetic protein, intralesional candida 
antigen46.
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TOPICAL THERAPY
The mode of action and effects are as 
follows.
Immunosuppressants - Topical steroids of class 1 
to 5 are effective in alopecia areata, but takes 
several months for elicitation of hair growth. 
They can be either used with or without occlusive 
dressing.  Most  of  the  studies  have  used 
flucinolone and halcinonide. Side effects include 
folliculitis,  hypertrichosis,  acneiform 
eruptions, local atrophy or chronic dilatation of 
capillaries  leading  to  red  blotchy  patches. 
Before  being  used  in  the  periocular  region,  a 
preliminary eye examination or regular follow up 
examinations  must  be  done  for  glaucoma  and 
cataract. Children requiring high doses of class 
I or class II topical corticosteroids need to be 
monitored to control systemic side effects.
Intralesional  steroids47,48,49 -  Depot  corticosteroid 
injected intralesionally stimulates hair regrowth 
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at the site of injection. Hydrocortisone acetate 
(25 mg mL[-1]) and triamcinolone acetonide (5-10 
mg mL[-1]) are commonly used. Corticosteroid is 
injected  just  beneath  the  dermis  in  the  upper 
subcutis. A 0.05-0.1 mL injection will produce a 
tuft of hair growth about 0.5 cm in diameter. 
Treatment  is  repeated  every  4  –  6  weeks. 
Intralesional  steroids  are  administered  with  a 
needleless device (dermajet)/ tuberculin syringe 
or  insulin  syringe.  Repeated  injection  at  the 
same site or the use of higher concentrations can 
lead  to  reversible  local,  perilesional,  or 
perilymphatic atrophy or systemic toxicity. Risk 
of cataract and raised intraocular pressure is 
high  if  intralesional  corticosteroids  are  used 
close  to  the  eye.  Rarely  anaphylaxis  and 
amaurosis  have  been  reported.  Intralesional 
corticosteroids is of little practical value if 
hair loss is extensive.
36
CONTACT SENSITIZERS 4,37,50,51,52,53
Topical  immunotherapy  is  the  most  effective  and  accepted 
modality  in  the  treatment  of  AA.  The  mechanism  of  action  of  local 
sensitizers is by immunomodulation. There is a decrease in the peribulbar 
CD4+/CD8+ lymphocyte ratio, a shift in the position of T lymphocytes 
away from perifollicular areas to the inter follicular areas and dermis. The 
following are the two concepts of local immunomodulation, they are that 
effector T cells are attracted in that area. There is probably a localized 
antigen  competition  occurring  and  that  repeated  application  activates 
nonspecific suppressor responsible for AA. Three contact sensitizers used 
are  squaric  acid  dibutyl  ester(SADBE),  dinitrocholorbenzene  (DNCB) 
and diphenylcyclopropanone (DPCP). SADBE or DPCP are widely used 
immunogen  though  DNCB  has  be  reconsidered  as  its  been  used  for 
treatment of chronic resistant cases of AA. SADBE is not found in the 
natural environment, doesn’t cross react with other chemicals and is not 
mutagenic. The disadvantage is that it is not stable.
Diphenylcyclopropenone53 (DPCP) is also an accepted modality for 
treatment of severe AA. One study demonstrated a 70% response rate in 
DPCP-treated patients  with severe  alopecia  areata  affecting  more  than 
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40% of the scalp. Pruritus, dermatitis, urticaria, face and scalp edema and 
the development of vitiligo are known side effects of DPCP use. 
DNCB50,52 powder  is  dissolved  in  acetone  and  diluted  in 
appropriate concentrations of 0.001%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 
1.5% and 2% solutions.  Solution is  stored in dark bottles  until  use in 
room  temperature.  DNCB  is  applied  using  cotton  buds.  Sensitization 
done by applying 2% DNCB over 4 x 4 cm area on back during the first 
visit. After 2 weeks, weekly applications of DNCB is continued starting 
with  lowest  concentration  (0.001%)  to  the  affected  area  of  hair  loss. 
Patients  are  advised  to  avoid  washing  the  area  and to  protect  it  from 
sunlight for 48 hours. Applications of DNCB are repeated weekly with 
increasing concentrations. The aim of the treatment is to maintain a low 
grade tolerable erythema and pruritus on the treated side for 24 to 36 hrs 
after application. Mild to moderate eczema was maintained by titrating 
the  DNCB  concentrations.  Untoward  effects  includes  eczematous 
reactions  with  or  without  blistering  or  extension  of  allergic  contact 
dermatitis  to  other  areas,  itching  and  oedema  of  the  face  and  scalp, 
regional lymphadenopathy and post inflammatory hyperpigmentaion or 
hypopigmentatiton.  Contact  urticaria,  vitiligo and erythema multiforme 
have also been reported. Contact  sensitizers are contraindicated during 
38
pregnancy. Once hair growth is established on one side the next side is 
treated. If there was no sensitivity even after 12 weeks, it was considered 
as treatment failure and the patient can be withdrawn.
IRRITANTS
Anthralin30,54 –  Anthralin  has  been  used  in  treatment  of  AA in 
concentration  of  0.25  to  1.0%.  It  may  have  a  non-  specific 
immunomodulating effect in eliciting hair growth. Short contact therapy 
is effective and cosmetically  acceptable regrowth has been reported to 
vary  from 20  to  25%.  Anthralin  0.5% to  1%  cream may  be  applied 
overnight or as a short contact therapy initially for 30 mins and gradually 
increased to one hour with 1% anthralin cream. When therapy is effective 
new hair growth is seen usually within 3 months. It may take 24 or more 
weeks for cosmetically acceptable response. Anthralin is a good choice 
for  children.  Adverse  effects  include irritation,  scaling,  folliculitis  and 
regional lymphadenopathy. Patients should be advised to protect treated 
area from sunlight,  avoid getting anthralin into the eye and be warned 
about staining of the treated skin and clothes that come in contact with 
anthralin.
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Onion Juice55 – Sharquie KE et al showed in a 
study  that  the  use  of  crude  onion  juice  gave 
significantly higher results with regard to hair 
re-growth than did tap water and that it can be 
an effective topical therapy for patchy alopecia 
areata.  In  his  study  patients  were  advised  to 
apply the crude onion juice twice daily for two 
months.  Re-growth  of  terminal  coarse  hairs 
started  after  two  weeks  of  treatment. High 
amounts  of  sulphur  in  onions  make  them 
particularly  effective  in  regenerating  hair 
follicles  and  stimulating  hair  regrowth.  In 
addition,  naturally-concentrated  sulphur 
compounds  have  been  proven  to  show  additional 
hair-restoring function.
Tretinoin56,57 – Retinoids are normally used in 
the treatment of acne vulgaris, however has more 
recently  been  used  in  the  treatment  of  both 
Alopecia  areata  and  Androgenetic  alopecia. 
Topical tretinoin appeared to enhance the hair 
growth  producing  effect  of  the  intralesional 
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triamcinolone. Tretinoin helps to normalize cell 
differentiation,  and  the  familiar  retinoid 
dermatitis may contribute to the stimulation of 
hair growth by creating an immune response. It 
also  acts  through  inhibition  of  toll  like 
receptors -2 and hence reduces the inflammation. 
Usually retinoids in a gel form is rubbed on the 
area of hair loss. The gel works best when used 
in  combination  with  topical  Minoxidil.  It  is 
suggested  that  Minoxidil  be  applied  in  the 
morning and retinoids in the evening due to the 
fact  that  retinoids  increase  the  skin’s 
sensitivity to sunlight.
PHOTOCHEMOTHERAPY
Topical Puva Therapy 58,59  – Orally administered PUVA  therapy 
has been one among the numerous available modalities in the treatment 
of alopecia areata. The use of oral PUVA is often limited by systemic 
side effects. Hence PUVA has been used topically. It has also been used 
in the form of turban,  where towels soaked in 0.0001% of 8 methoxy 
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psoralen are wrapped around the patients head in a turban fashion, for a 
period of 20 mins and then it was followed by UVA irradiation.
PUVA therapy results for alopecia areata are highly varied – the 
major problem with PUVA is the high relapse rate. Circumscribed lesions 
respond better than total alopecia and total body PUVA is probably more 
effective  than  local  irradiation.  Follow  up  studies  of  large  group  of 
patients have shown that PUVA in general is not an effective treatment 
options. 
CRYOTHERAPY
Liquid Nitrogen60  –  Liquid nitrogen is an efficient, simple, cheap 
modality of therapy without any troublesome side effects which relies on 
the  induction  and  maintenance  of  skin  inflammation  by  repeated 
application of an irritant. Lei et al used a cotton swab dipped in liquid 
nitrogen to the patches of AA, for 2 freeze thaw cycles of 2 to 3 seconds 
at an interval of 2 to 3 seconds. This treatment was repeated once weekly 
for 4 to 6 weeks and new hair growth was noticed in over 60% of the 
areas involved. Mechanism of action of liquid nitrogen may be due to 
improved blood circulation to the hair follicles thus promoting nutrition 
and  acceleration  of  hair  growth.  The  adverse  effects  noted  were 
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insignificant and included mild swelling, hyperesthesia and mild itching 
in the treatment area for a few hours following treatment. 
OTHERS
Topical Tacrolimus61,62 –Initial trials of tacrolimus were promising 
and has induced anagen phase of hair growth.
Topical Minoxidil63,64,65,66 – (2– 4 Diamino 6 piperidino pyrimidine 
3 oxide) minoxidil is a powerful vasodilator. It causes direct relaxation of 
arteriolar  smooth  muscle  with  little  effect  on  venous  capacitance.  Its 
effect  on  alopecia  areata  is  by  stimulation  of  DNA synthesis  in  hair 
follicles.  It  has direct  effect  on the proliferation and differentiation  of 
keratinocytes  invitro  and  regulates  hair  physiology  independently  of 
blood  flow  influences.  Cosmetically  acceptable  hair  growth  has  been 
reported  in  20 to  45% of  the  patients.  It  is  probably  not  effective  in 
alopecia universalis  and totalis.  Side effects  are rare and include local 
irritation, allergic contact dermatitis and facial hair growth.
Encouraging  results  have  been  obtained  with  xenon  chloride 
excimer laser (308 nm) and pulsed infrared diode laser (904nm)1
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SYSTEMIC THERAPY1,30,37,67
Systemic Steroids – Probably have a role in controlling the spread of 
the  disease.  They  are  very  effective  but  its  use  is  reduced  due  to  its 
adverse effects.  Pulse therapy have been used in the treatment of AA. 
Systemic steroids have been used in the following regimens:
1. Methyl prednisolone – (i.v) 500mg/day for 3 consecutive days 
or 5 mg/kg body weight b.i.d for 3 days every 4 weeks
2. Prednisolone 40 – 60 mgm and to taper by 5 mgm every week/ 
some recommend oral monthly pulse of 300mg68
3. Oral minipulse therapy – Dexamethasone 5 mg twice weekly on 
two consecutive days for  3  to 6 months,  2.5 – 3.5 mgm for 
children less 12 years. 
PUVA69
Oral  PUVA  has  been  used  in  the  treatment  of  alopecia  areata. 
Claudy  et  al  proposed  that  PUVA  acts  through  systemic 
immunomodulation they also suggested that oral methoxsalen and whole 
body PUVA were more useful than local PUVA therapy. However over 
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the long term use PUVA produced cosmetically acceptable results only in 
10% of the cases.
OTHER SYSTEMIC MODALITIES
Sulfasalazine –  70  It  acts  through  inhibition  of  chemotaxis  and 
synthesis of various cytokines and antibodies. Ellis et al found it to be 
efficacious  and  proposed  that  it  should  be  started  at  500mg/day  and 
gradually increased by 500mg weekly to reach a daily dose of 3 g to be 
continued for atleast four months. Others include cyclosporine, inosiplex 
and intravenous immunoglobulin71 for AA treatment. 
In conclusion, the future therapeutic options include recombinant 
human  bone  morphogenetic  protein  as  the  latter  is  involved  in  hair 
morphogenesis  and  certain  biologicals  like  efalizumab,  humanized 
monoclonal anti- CD11a antibody also show promising future.
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AIMS OF STUDY
The aims of the present study was 
1.  To study the efficacy of various modalities of 
treatment & to compare them with one another.
2. To study the adverse effects of the various 
modalities used.
The various modalities of treatment used in the present 
study were
i. Topical tacrolimus (0.03%)
ii. Topical tretinoin (0.025%)
iii. Topical minoxidil (2%)
iv. Topical anthralin (0.5%)
v. Intralesional steroids
vi. Topical crude onion juice 
vii. Topical DNCB
viii. Topical steroid 0.1% betamethasone ointment
ix. Cryotherapy with liquid nitrogen.
x. Control group
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MATERIALS & METHODS
Patients  presenting  with  AA  to  the 
Dermatology Department of our hospital during the 
study period August 2007 to September 2009 were 
recruited for the study. A diagnosis of AA was 
made on clinical grounds, based on the following 
criteria.
Asymptomatic, well circumscribed, smooth, non 
scaly, non scarring patch of hair loss on the 
scalp. Mycology opinion & fungal scraping from 
the patch was done to rule out tinea capitis in 
doubtful cases. A thorough history was elicited 
with regards to the duration of symptoms, disease 
progression, history of past episodes, history of 
any  topical/  systemic  treatment,  history 
suggestive  of  any  psychiatric  disturbances  & 
septic  foci,  a  personal  &  family  history  of 
atopy,  other  dermatoses,  diabetes  mellitus, 
hypertension and history suggestive of any other 
autoimmune disease were also elicited.
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A meticulous general & systemic examination 
was  performed.  Complete  dermatological 
examination was performed taking care to note any 
other dermatosis in the patient. Nail changes and 
mucosal changes were noted.
The  location  of  the  patches  of  AA,  with 
reference to the size, presence of hair in the 
patches  was  also  made.  The  presence  of 
exclamation  hair  mark,  coudability  sign  & 
pluckability  of  hair  at  the  margins  was  also 
recorded.  Presence  of  erythema  &  scaling  if 
present at the margins of the patch were noted.
A complete hemogram, ENT & dental opinion to 
rule out septic foci was carried out in all the 
patients & RBS in adults was done. The individual 
with history of exposure to the risk of STD were 
subjected to a blood VDRL examination.
After  completing  the  examinations  &  making 
the necessary exclusions (children < 12 years, 
pregnancy)  100  patients  were  taken  in  the 
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therapeutic  study  &  were  allocated  treatment 
randomly. Before starting the therapy appropriate 
treatment of focal sepsis if any were given to 
patients.  The  patients  were  divided  into  ten 
groups  comprising  10  in  each  group  &  the 
following therapy was instituted.
GROUP  1:  PATIENTS  SUBMITTED  FOR  TOPICAL 
TACROLIMUS 0.03%
Ten  patients  comprising  the  1st group  were 
treated with topical tacrolimus 0.03%, patients 
were advised to apply it daily every night over 
the AA patches. Patients were asked to continue 
the  treatment  until  acceptable  hair  growth 
occurred or till the end of the study period that 
is 3 months.
GROUP 2: PATIENTS TREATED WITH TOPICAL TRETINOIN 
0.025%
Ten  patients  were  treated  with  topical 
tretinoin (0.025%). Patients were asked to apply 
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it topically over AA patch only during night and 
were followed up till the end of study period.
GROUP 3: PATIENTS TREATED WITH 2% MINOXIDIL
10 patients were treated with 2 % topical 
minoxidil, the patients were advised to apply few 
drops evenly over the patches not exceeding by 
1ml/day twice daily and followed up till the end 
of the study period.
GROUP  4:   PATIENTS  TREATED  WITH  0.5%  TOPICAL 
ANTHRALIN
10 patients were treated with 0.5% topical 
anthralin.  A  short  contact  therapy  was  used. 
Patients were advised to apply a small quantity 
of  0.5%  anthralin  initially  for  10  mins  & 
subsequently the contact period was increased to 
30 mins. After 30 mins the ointment was removed 
with  a  cotton  swab  followed  by  hair  wash. 
Patients  were  cautioned  to  wash  hands  after 
applying anthralin, to protect the treated skin 
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against sun exposure and to be aware of staining 
clothes and linen.
GROUP  5:  PATIENTS  TREATED  WITH  INTRALESIONAL 
STEROID
10  patients  were  treated  with  monthly 
injection of steroid intralesionally in the AA 
patch. Patients were reviewed monthly before the 
next injection for any side effects and injection 
was given till acceptable hair growth occurred 
during the study period.
GROUP 6: PATIENTS TREATED WITH CRUDE ONION JUICE
10 patients were treated with onion juice. 
Patients were applied with extract of crude onion 
juice over the AA patch till the period of study.
GROUP 7: PATIENTS TREATED WITH TOPICAL DNCB
Ten patients were treated with topical DNCB. 
Initially  2%  concentration  of  DNCB  in  acetone 
solution  was  applied  to  a  small  area  and  was 
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advised for photoprotection for 48 hrs & to wash 
it off after that. Two weeks later the scalp is 
painted with a weak solution of DNCB, starting at 
0.001% and this is repeated at weekly intervals. 
The concentration is increased at each treatment 
until a mild dermatitis reaction is obtained. The 
frequency  of  treatment  is  reduced  after  the 
growth has been obtained and discontinued after 6 
months if no positive response occurs.
GROUP  8:  PATIENTS  TREATED  WITH  TOPICAL  0.1% 
BETAMETHASONE OINTMENT
Ten  patients  were  treated  with  topical 
steroid ointment containing betamethasone & were 
advised  to  apply  it  at  night  until  acceptable 
hair growth occurred or until end of the study.
GROUP 9: PATIENTS SUBMITTED FOR LIQUID NITROGEN 
THERAPY
Ten  patients  were  treated  with  liquid 
nitrogen. It was applied over the patches of AA 
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with a cotton wool liquid applicator producing 2 
– 3 freeze thaw cycles at an interval of 2- 3 
seconds  until  an  erythema  developed  over  the 
patches. This treatment was repeated every week, 
until acceptable hair growth occurred or till the 
end of the study period that is 3 months. 
GROUP 10: PATIENTS SUBMITTED FOR PLACEBO
Ten  patients  were  not  given  any  specific 
treatment (only multivitamins).
Al the patients were reviewed once in 15 days 
for 3 months and were graded as follows.
During follow up the following changes were 
noted and recorded.
1) Increase in size of the lesions.
2) Appearance of new lesions
3) Response to therapy was noted as follows
a. no growth of hair
b. appearance of vellus hair
c. growth of pigmented normal hair
d. extent of regrowth
53
4) Complications of therapy like
a.burning and irritation
b.erythema
c.vesiculation
d.pigmentary changes
e.folliculitis
f.atrophy etc. were also recorded.
Response grading to therapy was in the 
following manner.
0 – 
25% A
Hair regrowth covering < 25% of the 
patch. Vellus regrowth was not taken 
into account.
Very poor response
25 – 
50% B
Hair  regrowth  occurs,  but  is  not 
cosmetically  acceptable  to  the 
patients.
Poor response
50 – 
75% C
The  hair  regrowth  is  cosmetically 
acceptable  and  cover  3/4th of  the 
patch.
Moderate response
75 – 
90% D
The hair regrowth covered almost all 
of the patch, but the hair was not 
of  similar  density  to  the 
surrounding hair.
Good response
90 E Complete regrowth of hair, which is 
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-100%
indistinguishable  from  the 
surrounding area.
Excellent response
For  the  purpose  of  statistical  analysis, 
comparison  &  interpretation  patients  with 
excellent,  good  &  moderate  response  were 
considered to be improved and those patients with 
very poor and poor response were considered to be 
not improved. Also a mean score for each response 
were allotted as follows: (Table No:12)
A – 1, B – 2, C – 3, D – 4 & E – 5.
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OBSERVATIONS
An analysis of the clinical profile of the 
patients recruited for the therapeutic response 
revealed the following data.
There were 40 females & 60 males in the study 
groups.
The age of the patient ranged from 13 to 50 
years and the average age is 27.72 years.
The duration of the disease ranged from one 
week  to  4  years,  average  duration  being  4.7 
months.
5 patients had a family history of atopy. 
There  was  a  personal  history  of  atopy  in  20 
patients  in  the  form  of  allergic  rhinitis, 
urticaria (11), pitryiasis alba in one patient.
A thorough history and examination revealed 
rheumatic  mitral  stenosis  in  one  patient  and 
valvotomy  was  done  for  this  patient,  one  had 
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hyperthyroidism  with  PCOD,  one  patient  had 
history of TB and another one had oral submucosal 
fibrosis.  Almost  all  the  patients  had  single 
episode  except  for  12  patients  who  had  >1 
episode.  In  addition  to  the  family  history  of 
atopy recorded earlier 12 & 5 patients had family 
history of DM and hypertension.
Examination of the patches of AA revealed the 
following:
The number of patches varied from 1 to 8, the 
average being 1.8. The size of the smallest patch 
was 0.5cm and the size of the largest patch was 6 
X 6 cm. The coudability sign and exclamation mark 
hair were positive only in 3 patients.
The  regionwise  distribution  of  the  patches 
were occipital (34), parietal (24), frontal (29) 
and temporal (20). The nail changes noticed were 
pitting in 13 patients, leuconychia in 10, linear 
grooves  in  5,  melanonychia  in  3  patients.  Two 
patients had hyperpigmentation of oral mucosa.
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Other  associated  dermatological 
manifestations  were  tinea  corporis,  pityriasis 
versicolor,  psoriasis,  lichen  planus  and 
seborrheic  dermatitis  in  3  patients.  Clinical 
examination  of  focal  sepsis  revealed  chronic 
gingivitis in 22 patients, dental caries in 24 
and pharyngitis in 2 patients.
OBSERVATION OF THERAPEUTIC RESPONSES
GROUP I: RESULTS OBTAINED WITH TOPICAL TACROLIMUS 
0.03%.
Among  the  10  patients  treated  with 
tacrolimus, 3 patients showed excellent response 
&  2  patients  each  showed  good  &  moderate 
response. Poor response was seen in 2 patients 
and  very  poor  response  in  one  patient  (Table 
no:1) Regrowth of hair started after 2 weeks in 
one, after 4 weeks in 3 patients with excellent 
response. Patients with very poor response showed 
no growth at all except for vellus growth of hair 
which was poor during the entire study period. 
One patient with excellent response had developed 
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new patches elsewhere.
Gp I: (TABLE NO: 1) CLINICAL PROFILE OF PATIENTS 
ON TOPICAL TACROLIMUS (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 24 14 33 41 19 34 13 31 27 15
Sex M F M M M M F M M F
No. of 
patches
3 2 1 2 1 1 1 1 1 1
Dur. 
(months)
5 12 1 6 8 7 1w
k
2 6 4
Cum. resp. E E D E D C C B B A
The untoward effect noticed by the patient 
were transient burning sensation, others include 
mild erythema & headache, but this resolved later 
after continued application.
GROUP II: RESULTS OBTAINED WITH TOPICAL TRETINOIN 
(0.025%)
Moderate regrowth of hair occurred in three 
out of 10 patients in this group. Excellent and 
good response were seen in one patient each. Two 
patients  showed  very  poor  response  and  three 
patients showed a poor response (Table no: 2). In 
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patients  with  excellent  response,  regrowth 
started after 2 weeks & was complete by 14 weeks. 
In  patients  with  good  and  moderate  response 
regrowth  started  at  4  weeks.  In  patients  with 
poor and very poor response regrowth started at 
10 wks. Only one patient showed extension of the 
existing lesion during the study period.
Gp II: (TABLE NO:2) CLINICAL PROFILE OF PATIENTS 
ON TOPICAL TRETINOIN (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 13 30 50 21 27 42 32 35 30 26
Sex F F F M M M F F F F
No.of 
patches
2 3 2 1 2 1 2 1 1 2
Dur.
(months)
6 5 12 8 3 1 1 2 5 2
Cum. Res. B A E C D C C B A A
Four patients reported mild burning sensation 
in  the  patches  on  sun  exposure  alone  &  these 
patients were advised sun protection. 
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GROUP III: RESULTS OBTAINED WITH 2% MINOXIDIL
Acceptable regrowth of hair occurred in 9 out 
of 10 patients in this group. Excellent response 
was  seen  in  four  patients,  good  response  in 
three, moderate response in two patients and very 
poor response in one ( Table no: 3)
Gp III: (TABLE NO:3) CLINICAL PROFILE OF PATIENTS 
ON 2% MINOXIDIL (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 26 26 24 38 28 22 12 45 40 20
Sex M M M F M F F M F F
No. of 
patches
1 1 2 1 1 1 1 1 1 1
Dur.
(months)
5 2 5 6 3 2 0.5 3 2 3
Cum. Res. E D E E D D E C C A
Regrowth of hair occurred at the end of 2 
weeks in two patients with excellent response & 
after 4 weeks in two patients. All the patients 
showed complete hair regrowth at the end of 12 
weeks. Patients with good response showed hair 
regrowth after 4 weeks. In one of the patient 
with moderate response, though the patch showed 
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complete hair growth, the patches continued to 
increase in size at the margins, in the other 2 
patients  with  moderate  response  regrowth  was 
noticed  at  8  wks.  The  patient  with  very  poor 
response  did  not  show  any  evidence  of  hair 
regrowth & the patch was in beard region.
None  of  the  patients  complained  of  any 
adverse effects to the medication nor were any 
signs of irritation noticed during the follow up 
period.
GROUP IV: RESULTS OBTAINED WITH 0.5% 
ANTHRALIN:
Acceptable regrowth of hair occurred in four 
out  of  ten  patients  in  this  group,  excellent 
response was seen in two patients, good response 
in one, moderate and poor response one each and 
very  poor  response  was  seen  in  five  patients 
(Table no: 4).
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Gp IV: (TABLE N0:4) CLINICAL PROFILE OF PATIENTS 
ON 0.05% ANTHRALIN ( n = 10)  
Case no. 1 2 3 4 5 6 7 8 9 10
Age 12 32 36 25 35 25 15 52 14 28
Sex F M F M F F M F M M
No.of 
patches
8 1 2 1 3 1 1 1 1 1
Dur.
(months)
12 3 6 0.5 4 1 1.5 3 12 1
Cum. Res. A A E A A B D E C A
In  the  patient  showing  excellent  response, 
hair  regrowth  started  at  4  to  6  weeks  with 
gradual  increase  in  thickness  of  the  hair. 
Patient with good response showed hair regrowth 
after 4 weeks. In the patient with poor response 
the hair started regrowing only at 6 weeks & it 
was vellus hair that growed initially. Patients 
with  very  poor  response  showed  no  regrowth  at 
all. 
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The main adverse effect noticed was staining 
of the area of alopecia & stinging sensation. One 
patient developed folliculitis & patch edema. 
GROUP  V:  RESULTS  OBTAINED  WITH  INTRALESIONAL 
STEROIDS
Acceptable regrowth was seen in nine out of 
ten  patients.  In  this  group  5  patients  showed 
excellent  response;  four  showed  good  response; 
rest  each  one  patient  showed  moderate  &  poor 
response (Table no:5)
Gp V: (TABLE NO:5) CLINICAL PROFILE OF PATIENTS 
ON INTRALESIONAL STEROIDS (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 45 17 10 25 26 35 16 32 33 16
Sex M M M M M M F F M F
No.of 
patches
1 2 2 1 1 1 3 2 1 2
Dur.
(months)
2 6 2 2 5 3 3 4 2 2
Cum. Res. E E D B E E D D E D
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All the five patients with excellent response 
& one patient with moderate response showed hair 
regrowth after 4 weeks. Out of four patients with 
good response two patients showed appearance of 
new patch when on treatment.
Patient with a poor response developed local 
atrophy at the injection site following a single 
session.  Most  of  the  patients  showed  hair 
regrowth after single injection of intralesional 
steroid but cosmetically acceptable results were 
obtained after two sessions.
GROUP VI: RESULTS OBTAINED WITH ONION JUICE: 
Among  the  10  patients  treated  with  onion 
juice  one  patient  showed  excellent  response, 
three showed good response, two showed moderate 
response and two of each patient showed poor and 
very poor response ( Table no: 6). In patient 
with excellent regrowth the hair growth started 
at 4 weeks. Acceptable regrowth was seen in five 
patients  with  growth  starting  after  2  weeks. 
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Patients with poor and very poor response showed 
fine vellus hair at the end of the study period. 
The main adverse effect that was noted is contact 
dermatitis,  two  patients  showed  erythema  and 
scaling. One showed few areas of hypopigmentation 
within the patch.
Gp VI: (TABLE NO: 6) CLINICAL PROFILE OF PATIENTS 
ON CRUDE ONION JUICE (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 41 30 21 28 35 30 32 25 42 18
Sex M M M F M M F M M M
No. of 
patches
1 1 1 2 2 1 2 1 1 1
Dur. 
(months)
2 3 2 4 3 1 5 2 3 4
Cum. Res. D C B D D B A C A E
GROUP VII: RESULTS OBTAINED WITH TOPICAL DNCB
Out of ten patients excellent response was 
seen in two patients, two patients each showed 
good  and  moderate  response  and  three  patients 
showed  poor  response  and  one  showed  very  poor 
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response (Table no: 7). Patients with excellent 
response showed regrowth after 4 weeks, and the 
effect  was  sustained  till  the  patient  was 
followed up in the study period. One patient with 
good  response  had  occurrence  of  new  lesion 
elsewhere  on  the  scalp  during  the  course  of 
treatment.  One  patient  with  oophiatic  pattern 
showed  no  growth  at  all.  Patients  with  poor 
response showed few fine vellus hair regrowth.
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GpVII: (TABLE NO:7) CLINICAL PROFILE OF PATIENTS 
ON DNCB (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 38 30 40 35 28 16 26 32 45 37
Sex M M M M M M M F F F
No.of 
patches
AU O 2 2 8 1 2 3 2 1
Dur.
(months)
24 84 6 4 2 3 0.5 2 2 1
Cum. Res. B A D C B D E B E C
The  commonest  side  effect  encountered  was 
burning sensation. Two patients had mild erythema 
at the site of application. Lymphadenopathy was 
seen in one patient.
GROUP VIII: RESULTS OBTAINED WITH TOPICAL 0.1% 
BETAMETHASONE OINTMENT
Acceptable regrowth of hair occurred in six out of 
ten  patients  in  this  group.  Three  patients  showed 
excellent  response,  two  showed  good  response  and  one 
showed moderate response, poor and very poor response was 
seen in one patient each (Table no:8)
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Gp  VIII:  (TABLE  NO:8)  CLINICAL  PROFILE  OF 
PATIENTS ON 0.1% BETAMETHASONE
Case no. 1 2 3 4 5 6 7 8 9 10
Age 14 30 29 30 18 13 31 18 18 12
Sex F M M M F F F F F F
No. of 
patches
2 1 2 3 1 2 3 2 3 1
Dur. 
(months)
24 1 3 3 3 12 2 3 3 3
Cum. Res. B C E A E B D B E A
In  all  the  three  patients  with  excellent 
response, regrowth started after 2 weeks and in 
one  of  them  it  was  complete  by  12  weeks.  In 
patients with good and moderate response regrowth 
started at 4 weeks. In patients with poor and 
very poor response, regrowth started only at 8 
weeks. One patient with diffuse type of AA the 
response was very poor.
No  adverse  effects  of  the  therapy  were 
noticed on observation or reported by the patient 
during the study period.
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GROUP IX: RESULTS OBTAINED WITH CRYOTHERAPY
Acceptable regrowth occurred in nine out of 
10 patients of whom excellent response was seen 
in five patients, good response in one patient 
and moderate response in two patients. Each of 
one patient showed poor and very poor response 
(Table no:9)
Gp IX: (TABLE NO: 9) CLINICAL PROFILE OF PATIENTS 
ON CRYOTHERAPY (n=10)
Case no. 1 2 3 4 5 6 7 8 9 10
Age 33 28 25 15 30 10 40 28 40 35
Sex M M F F F F M M M M
No. of 
patches
1 1 3 4 2 3 1 1 5 1
Dur. 
(months)
3 6 0.5 6 1 0.7
5
6 6 3 2
Cum. Res. D E E E E C A E C B
In patients with excellent response regrowth 
of hair started after 2 weeks in one, and after 4 
weeks in three. In the patient with very poor 
response  the  regrowth  was  noticed  only  at  8 
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weeks. Patient with good response showed increase 
in size of the patch initially. New patch was 
noticed in patient with moderate response.
The  side  effect  commonly  reported  by  the 
patients were burning, stinging sensation at the 
time  of  LN  application.  One  of  the  patient 
developed  depigmentation  at  the  site  of 
application. Patient with a poor response showed 
sparse vellus hair.
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GROUP X:  RESULTS OBTAINED WITH CONTROL GROUP
Out of the ten patients two patients showed 
acceptable  regrowth.  One  patient  each  showed 
moderate response. Most of the patients showed no 
hair regrowth at all even after completion of the 
study period ( Table no:10). Two patients showed 
fine  vellus  hair  regrowth.  One  patient  with 
moderate response showed hair regrowth only after 
6 weeks. One patient of this group complained of 
itching at the site of the patch. 
Gp X: (TABLE NO:10) CLINICAL  PROFILE OF PATIENTS 
ON PLACEBO ( n = 10 )
Case no. 1 2 3 4 5 6 7 8 9 10
Age 35 21 18 36 31 31 29 30 18 25
Sex M F F M M M F F F M
No of 
patches
2 1 4 2 1 2 2 1 1 1
Dur. 
(months)
6 2 6 12 12 5 3 3.
5
2 3
Cum. Res. B B A A A C A C B A
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TABLE NO: 11 COMPARISON OF PROPORTION OF
IMPROVEMENT AMONG DIFFERENT STUDY GROUPS
Group
Improved Not improved
Overall
P-Value*
Significant 
groups at 
5% level$
No % No %
I 7 70 3 30
0.03 (Sig.)
[X2 = 18.51, 
d. f. = 9]
III vs. X
V vs. X
IX vs. X
II 5 50 5 50
III 9 90 1 10
IV 4 40 6 60
V 9 90 1 10
VI 6 60 4 40
VII 6 60 4 40
VIII 6 60 4 40
IX 8 80 2 20
X 2 20 8 80
*Chi-square test was used to calculate the P-Value
$Chi-square  with  Yates’  Continuity  Correction  or  Fisher’s  Exact  (2-tailed)  was 
employed to identify the significant groups at 5% level.
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TABLE NO: 12 RESPONSE OF HAIR REGROWTH IN TEN GROUPS 
WITH MEAN SCORE
Group A=1 B=2 C=3 D=4 E=5
I 1 2 2 2 3
II 3 2 3 1 1
III 1 0 2 3 4
IV 5 1 1 1 2
V 0 1 0 4 5
VI 2 2 2 3 1
VII 1 3 2 2 2
VIII 2 2 2 1 3
IX 1 1 2 1 5
X 5 3 2 0 0
A = Very poor, B = Poor, C = Moderate, D = Good, E = 
Excellent
TABLE NO: 13 COMPARISON OF MEAN SCORE AMONG 
DIFFERENT STUDY GROUPS
Group Mean ± S.D Overall P 
value*
Sig.groups 
at 5% 
level$
I 3.4  ± 1.4
0.004
(Sig.)
III vs. X
V vs. X
II 2.5  ± 1.4
III 3.9  ± 1.3
IV 2.4  ± 1.7
V 4.3  ± 0.9
VI 2.9  ± 1.4
VII 3.1  ± 1.4
VIII 3.1  ± 1.6
IX 3.8  ± 1.5
X 1.7  ± 0.8
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*Kruskal Wallis One Way ANOVA was used to calculate the P-value.
$
 Mann-Whitney U – Test followed by Bonferroni Correction 
method was employed to identify the significant groups at 
5% level.
TABLE NO: 14   COMPARISON OF PROPORTION OF 
IMPROVEMENT AMONG DIFFERENT STUDY GROUPS – SINGLE 
PATCH 
Groups SINGLE PATCH P value*
Improved Not improved
0.26 
(N.S)
[X2 = 
11.18, 
d. f. = 
9]
No. % No. %
I 4 57.1 3 42.9
II 2 50.0 2 50.0
III 8 88.9 1 11.1
IV 3 42.9 4 57.1
V 5 83.3 1 16.7
VI 4 80.0 3 42.9
VII 2 66.7 1 33.3
VIII 2 66.7 1 33.3
IX 4 80.0 1 20.0
X 1 20.0 4 80.0
*Chi-square test was used to calculate the P-Value
75
TABLE NO: 15   COMPARISON OF PROPORTION OF 
IMPROVEMENT AMONG DIFFERENT STUDY GROUPS – 
MULTIPLE PATCH
Groups
MULTIPLE PATCHES P value*
Improved Not improved
0.26 (N.S.)
[X2 = 
11.30, 
d. f. = 
9]
No. % No. %
I 3 100.0 0 0.0
II 3 50.0 3 50.0
III 1 100.0 0 0.0
IV 1 33.3 2 66.7
V 4 100.0 0 0.0
VI 4 66.7 2 33.3
VII 4 57.1 3 42.9
VIII 4 57.1 3 42.9
IX 4 80.0 1 20.0
X 1 20.0 4 80.0
*Chi-square test was used to calculate the P-Value
TABLE NO: 16  COMPARISON OF PROPORTION OF 
IMPROVEMENT AMONG SINGLE PATCH AND MULTIPLE 
PATCH - ATOPICS
Patch
Improved Not improved P 
value*
No. % No. %
1.00 
(N.S.)
Single 7 58.3 5 41.7
Multipl
e
4 50.0 4 50.0
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*Fisher’s Exact test (2-tailed) was used to calculate the P-Value
TABLE NO: 17 COMPARISON OF PROPORTION OF 
IMPROVEMENT AMONG SINGLE PATCH AND MULTIPLE 
PATCH – NON-ATOPICS
Patch
Improved Not improved P 
value**
No. % No. %
0.92 
(N.S)
Single 25 59.5 17 40.5
Multipl
e
24 63.2 14 36.8
** Chi-square test with Yates’ continuity correction was 
used to calculate the P value.
TABLE NO: 18   COMPARISON OF PROPORTION OF 
IMPROVEMENT   BETWEEN  ATOPICS AND NON ATOPICS
Patch
Improved Not improved
P 
value**
*
No. % No. %
0.80 
(N.S)
Single 11 55 9 45
Multipl
e
49 61.2 31 38.5
`
***Chi-square test with Yates’ continuity correction was 
used  to  calculate  the  
P value.
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TABLE NO: 19 COMPARISON OF MEAN AGE AMONG 
DIFFERENT STUDY GROUPS
Group Mean ± S.D Overall P 
value*
Sig. groups 
at 5% 
Level$
I 25.1 ± 9.7
0.31 
(N.S.) NIL
II 30.6 ± 10.4
III 28.1 ± 10.1
IV 27.4 ± 12.2
V 25.5 ± 10.9
VI 30.2 ± 7.8
VII 32.7 ± 8.2
VIII 21.3 ± 7.8
IX 28.9 ± 8.8
X 27.4 ± 6.6
* One way ANOVA  was used to calculate the P- value
$
 Tukey – HSD procedure was employed t identify the 
significant groups at 5% level.
TABLE NO: 20  COMPARISON OF GENDER AMONG 
DIFFERENT STUDY GROUPS
Groups
Male Female Overall P 
value*
No. % No. %
0.30 (N.S.)
[X2 = 
10.71,
d. f. = 9]
I 7 70 3 30
II 3 30 7 70
III 5 50 5 50
IV 5 50 5 50
V 7 70 3 30
VI 8 80 2 20
VII 7 70 3 30
VIII 3 30 7 70
IX 6 60 4 40
X 5 50 5 50
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*Chi-square test was used to calculate the P-Value
DISCUSSION OF THE THERAPEUTIC RESPONSES
GROUP  I:  PATIENTS  TREATED  WITH  TOPICAL 
TACROLIMUS
Cosmetically acceptable regrowth of hair in 
otherwords improvement was noticed in seven out 
of ten patients in the present study. Out of 7 
patients, three showed excellent response & two 
each showed good and moderate response.        
A study61,62 conducted by Vera and Price et al 
in Minneapolis where eleven patients treated with 
0.01% tacrolimus showed no terminal hair growth 
even after 24 weeks. This is in contrast to our 
study where regrowth of hair was noticed after 6 
weeks in six patients whereas 4 patients showed 
regrowth at 6 weeks.
All  the  three  patients  with  excellent 
response had multiple patches & all the patients 
with  good  and  moderate  response  had  single 
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patches. Rest of the three patients with single 
patches, two showed poor response & one showed 
very  poor  response.  This  shows  that  patients 
improved with both single and multiple patches 
and hence no significance was noted with regard 
to  number  of  patches.  Patients  with  good, 
moderate,  poor  and  very  poor  response  had  no 
personal or family history of atopy. One patient 
with  excellent  response  developed  new  patches 
else where. This showed that though treatment was 
initiated  it  did  not  alter  the  course  of  the 
disease  progression.  One  patient  with  moderate 
response had family history of hypertension and 
two  patients  with  good  response  had  chronic 
gingivitis and dental caries which was treated.
One patient with poor response had a minimum 
disease duration of one week & another patient 
with excellent response had a maximum duration of 
one  year  hence  the  disease  duration  doesn’t 
influence the outcome of the therapy.
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With seven patients showing good improvement 
without any adverse effects it can be concluded 
that tacrolimus could be considered to be one of 
the treatment modality. 
GROUP II: PATIENTS TREATED WITH TOPICAL 
TRETINOIN
Five out of ten patients improved in this 
group. Out of which one each showed excellent and 
good response & three showed moderate response. 
Hence 50% showed improvement and rest 50% did not 
show any improvement. Hass & Arndt57 et al showed 
the  beneficial  treatment  outcome  using  topical 
tretinoin with other combinations for hair growth 
disorders unlike our study where tretinoin alone 
was used. In this group 50% of the patients with 
single and multiple patch improved & 50% of the 
same did not show any improvement. Therefore the 
response outcome was not determined by number of 
patches. Two patients had a personal history of 
atopy & they showed poor and moderate response. 
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One patient with a family history of atopy showed 
a  good  response  and  he  also  had  history  of 
urticaria. Hence it can be presumed that atopy 
doesn’t  influence  the  response  outcome.  One 
patient  with  poor  and  very  poor  response  had 
family  history  of  diabetes  mellitus  and 
hypertension respectively. In this group all the 
three patients with very poor response had dental 
caries and the two patients with poor response 
had  chronic  gingivitis.  Further  studies  are 
needed to confirm the efficacy of this modality 
when used alone.
GROUP III: PATIENTS TREATED WITH  2% MINOXIDIL
90%  of  the  patients  in  this  study  group 
showed  improvement.  This  is  in  contrast  to  a 
regrowth  of  20  –  45%  reported  in  an  earlier 
study30.   Fiedler  Weiss  et64 al  have  shown  a 
response of 81% with 5% minoxidil solution versus 
a  38%  response  with  1  %  solution.  Except  one 
patient  all  the  patients  had  single  patch 
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involvement in contrast to other studies where 
multiple  patches  were  more.  In  patients  with 
improvement four had excellent response and two 
had moderate and three had good response. In four 
patients with excellent response one had history 
of atopy and others did not have any personal/ 
family  history  of  atopy,  diabetes  mellitus  or 
thyroid  disease.  Two  patients  with  personal 
history of atopy had good response which shows 
that  atopy  doesn’t  influence  the  response 
outcome.  One  patient  with  a  good  response  had 
hyperthyroidism  with  polycystic  ovarian  disease 
and was managed accordingly in the corresponding 
speciality department. One patient with moderate 
and  good  response  each  had  family  history  of 
diabetes  mellitus.  Two  patients  each  with 
moderate and excellent response had evidence of 
dental sepsis which was treated. One patient with 
a  poor  response  had  family  history  of 
hypertension and she had chronic gingivitis also. 
The  disease  duration  ranged  from  15  days  to 
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maximum  of  6  months  &  all  the  patients  with 
excellent response had a duration ranging from 15 
days to 6 months proving disease duration doesn’t 
modify the response outcome. 
Our study did not show any adverse effects in 
contrast to other studies3.Hence with 90% of the 
patients showing improvement minoxidil appears to 
be very promising treatment modality.
GROUP IV: PATIENTS TREATED WITH 0.05% 
ANTHRALIN
Four out of ten patient showed improvement. 
Two  patients  showing  excellent  response,  one 
patient  each  with  good  response  and  moderate 
response in others. Six out of ten patients did 
not show any improvement. This is little higher 
when compared to a response rate of 20 to 25% 
reported in the earlier study54.
Two patients with good and excellent response 
had personal history of atopy alone. One patient 
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with  poor  response  had  personal  history  of 
hypertension.  One  patient  each  with  good, 
moderate  and  very  poor  response  had  family 
history of diabetes mellitus. Acceptable regrowth 
of  hair  was  noticed  by  ten  weeks  in  three 
patients and 8 weeks in one of the patient, this 
is  in  contrast  to  24  weeks  reported  in  the 
earlier  studies64.Three  patients  with  very  poor 
response had chronic gingivitis and one patient 
with  poor  and  very  poor  response  had  dental 
sepsis which could be the possible cause for poor 
response to treatment. One patient with a good 
response  had  follicular  pharyngitis  which  was 
treated. Two patients with excellent response had 
both single and multiple patches. 42.9% of the 
patients with single patch improved whereas 33.3% 
of  the  patient  with  multiple  patches  showed 
improvement, rest of them did not improve. Thus 
no significance could be established with regard 
to number of patches. Also atopy did not appear 
to play any role like in previous modalities.
85
Scaling,  folliculitis  and  staining  of  the 
clothes were observed like in other studies. A 
large  study  may  be  necessary  for  the  exact 
assessement of topical anthralin.
GROUP V: PATIENTS TREATED WITH INTRALESIONAL 
STEROIDS
90%  of  the  patients  showed  considerable 
improvement  in  this  group.  5  patients  showed 
excellent response, four showed good response and 
one showed poor response. Chang, Kyung Hee49et al 
showed in his study that six out of ten patients 
showed  considerable  improvement  in  contrast  to 
our study where 90% improvement occurred. About 
83.3%  of  cases  with  single  patch  improved  and 
100%  improvement  occurred  in  patients  with 
multiple patches, unlike in other studies where 
extensive  AA  is  of  little  improvement47,48  which 
shows number of patches having no influence in 
the response outcome. One patient each with poor 
and good response had personal history of atopy. 
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Patient  with  poor  response  also  had  family 
history of atopy, with atopy being the probable 
cause of poor response. Two patients with good 
response had family history of diabetes mellitus. 
Two patients with excellent and good response had 
chronic gingivitis and dental sepsis which was 
treated. Out of ten patients treated, only one 
patient had atrophy at the site of injection. 
Intralesional  triamcinolone  acetonide  is  a 
safe and effective treatment for patients with 
extensive alopecia areata. Larger sample size and 
long term follow up are needed to assess the long 
term outcome of this treatment modality.
GROUP VI: PATIENTS TREATED WITH CRUDE ONION 
JUICE
Six patients showed improvement out of which 
one  had  excellent  response,  three  showed  good 
response and two showed moderate response. One 
patient each showed poor and very poor response. 
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Sharquie55 et al showed in his study that out of 
23  patients,  20  patients  (86.9%)  showed 
significant hair growth with crude onion juice. 
Males showed terminal hair regrowth than females 
similar to our study. Two patients with moderate 
response had personal history of atopy and both 
had single patches responding after 6 weeks of 
treatment.  57.1%  improvement  was  noticed  in 
patients with single patch and 66.7% improved in 
multiple patches with no significance in number 
of  patches  and  treatment  outcome.  One  patient 
with poor response had oral submucosal fibrosis. 
One patient with good response had family history 
of hypertension and diabetes. Two patients with 
good  response  and  one  with  poor  response  had 
dental caries and chronic gingivitis which was 
treated.  One  patient  had  irritant  contact 
dermatitis as a side effect. Further studies are 
needed to assess the long term outcome of this 
therapy.
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GROUP VII: PATIENTS TREATED WITH TOPICAL DNCB
Six out of ten patients showed improvement. 
Two  patients  had  excellent  response  and  two 
patients each showed good and moderate response. 
KH Mohan50,52 et al in his study concluded that out 
of  22  patients  36.36%  of  the  patients  showed 
complete  response  which  is  much  less  when 
compared  to  the  response  in  our  study.  One 
patient with poor response had personal history 
of  atopy  and  had  alopecia  universalis.  Hence 
atopy could have been the cause for this poor 
response.  One  patient  with  good  response  had 
family history of diabetes mellitus, rest of the 
patients  did  not  have  any  personal  or  family 
history of diabetes or hypertension. 66.7% of the 
patients  with  single  patch  and  57.1%  of  the 
patients with multiple patches showed improvement 
showing that number of patches doesn’t alter the 
response  outcome.  Two  patients  with  moderate 
response and one patient with excellent response 
had chronic gingivitis, also two patients with 
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poor response and one patient with good response 
had  dental  sepsis  which  was  treated.  The  only 
disadvantage of DNCB is its mutagenicity by Ames 
test. However, drugs like norfloxacin, isoniazid 
and psoralen with ultraviolet A (PUVA) treatment, 
textile dyes and fumes of oils have also been 
found  mutagenic  by  Ames  test.  DNCB  requires  a 
relook  as  an  option  in  alopecia  areata  rather 
than other contact sensitizers that are available 
only with difficulty and are expensive.
GROUP  VIII:  PATIENTS  TREATED  WITH  0.1% 
BETAMETHASONE OINTMENT
Six out of ten patients showed improvement. 
Three  patients  showed  excellent  response,  two 
patients showed moderate response and one showed 
good response. Two patients each showed poor and 
very poor response. Unlike most of the studies4 
conducted with 0.05% betamethasone diproprionate, 
our  study  was  done  with  0.1%  betamethasone 
valerate which had shown improvement similar to 
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other  studies  after  continuous  application  for 
three months with regrowth of terminal hair. Two 
patients with moderate response and one patient 
with very poor response had personal history of 
atopy and one patient with excellent response had 
family  history  of  atopy.  Therefore  it  can  be 
concluded  that  atopy  doesn’t  significantly 
influence the response outcome. 66.7% of patients 
with single patch and 57.1% of the patients with 
multiple patches showed improvement. Patient with 
excellent response had family history of diabetes 
mellitus. Two patients with moderate response and 
one  patient  with  good  response  had  chronic 
gingivitis  and  two  patients  with  very  poor 
response had dental sepsis which was treated. The 
poor response in the latter group might be due to 
the focal dental sepsis. 
From  this  study  it  can  be  concluded  that 
topical  steroid  remains  a  promising  treatment 
modality for alopecia areata.
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GROUP IX: PATIENTS TREATED WITH CRYOTHERAPY
Eight out of ten patients showed improvement 
and remaining 20% did not show any improvement. 
Five  patients  showed  excellent  response,  two 
showed  moderate  response  and  one  showed  good 
response. One patient each showed poor and very 
poor response. Lei60 et al in his study showed 
that hair regrowth occurred  in greater than 60% 
of affected areas in 70 of 72 patient, which is 
in  contrast  to  our  study  wherein  80%  of  the 
patients  showed  improvement.  Patients  with 
moderate  response  and  one  patient  with  good 
response  had  chronic  gingivitis.  Two  patients 
with excellent response and one patient with very 
poor response had dental caries. Hence in this 
group focal sepsis doesn’t seem to influence the 
response  outcome.  80.0%  of  the  patients  with 
single  and  multiple  patches  showed  improvement 
which shows that there is no significance in the 
number of patches in the response outcome. 
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From  the  above  it  can  be  concluded  that 
liquid nitrogen seems to be one of the cheap, 
cost effective therapy that could be tried in the 
treatment of alopecia areata.
GROUP X: PATIENTS TREATED WITH PLACEBO/ 
CONTROL GROUP
Out  of  ten  patients  two  showed  moderate 
response,  five  showed  very  poor  response  and 
three showed poor response. Antonella Tosti72 et 
al in his study showed in his placebo controlled 
trial  that  intervention  with  treatment  doesn’t 
possibly influence the response outcome, which is 
in contrast to our study. Out of five patients 
with very poor response, one had family history 
of  diabetes  mellitus  and  three  had  chronic 
gingivitis. One patient with poor response had 
history of tuberculosis and he had finished his 
anti tuberculous treatment. Out of three patients 
with  personal  history  of  atopy,  two  had  poor 
response and one had moderate response. Hence the 
response  was  not  dependant  on  the  presence  of 
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atopy.  All  the  latter  three  patients  also  had 
dental caries which was treated. Only 20% of the 
patients  with  single  and  multiple  patches  had 
improvement showing that number of patches were 
not significant in response outcome. Hence from 
this it can be concluded that there is only 20% 
chance  of  spontaneous  resolution  in  cases  of 
alopecia areata and that therapeutic intervention 
significantly  modifies  the  course  and  response 
outcome of the disease.
To  sum  up,  comparison  of  proportion  of 
improvement among different study groups showed 
that  only  groups  treated  with  intralesional 
steroids(90%),  topical  minoxidil  (90%)  and 
cryotherapy(90%) showed statistically significant 
improvement  (Table  No:11,12,13/  Fig  No:1)  than 
the  control  group(20%)  (P<0.05).  However,  no 
other  contrasts  are  statistically  significant 
(P>0.05).        
Comparison  of  mean  score  among  different 
study  groups  further  confirms  our  conclusion. 
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Also there is no significant difference in the 
proportion  of  improvement  among  various  groups 
(Table  no:14,15/  Fig  No:2,3)  for  single  patch 
(P=0.26) and multiple patches (P=0.26).
Comparison of proportion of improvement among 
single  and  multiple  patches  among  atopics 
(P=1.00) (Table No:16/ Fig No: 4) and among the 
non  atopics  (P=0.92)  (Table  No:17/  Fig  No:  5) 
showed no significant difference. Also there was 
no  significant  difference  in  improvement  among 
atopics and non atopics (P=0.08) (Table No:18). 
Statistically, there is no significant difference 
in mean age (P=0.31) (table no: 19) and gender 
distribution (Table No:20) among different study 
groups (P=0.31).
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CONCLUSION
1. Significant improvement occurred in patients 
treated  with  topical  minoxidil(90%), 
intralesional  steroids(90%)  and  cryotherapy 
with  liquid  nitrogen(90%)  than  the  control 
group(20%) treated with placebo.
2. All  the  three  significant  treatment 
modalities  produced  only  transient  adverse 
effects  which  did  not  interfere  with  the 
patient compliance.
3. Other  contrasts  (study  groups)  are  not 
statistically  significant  since  each  group 
comprised  of  ten  patients  only  (n=10)  and 
this  remains  the  limitation  of  our  study. 
Therefore studies in larger groups are needed 
are needed for further evaluation of other 
groups in our study. 
4. The  number  of  patches  (single/  multiple) 
among  different  study  groups  doesn’t 
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influence the response outcome (P=0.26).
5. Proportion  of  improvement  in  number  of 
patches ( single/ multiple) among atopics and 
the  non  atopics  was  statistically 
insignificant  and  hence  there  is  no 
correlation between atopy and the number of 
patches and its response outcome.
6. Atopy does not appear to be a significant 
factor in the response to therapy in patients 
with alopecia areata.
7. Atopy  in  the  form  of  personal  and  family 
history was the only significant association 
found in the present study group (20%).
8. There was no significant difference in the 
mean  age  and  gender  distribution  among 
different study groups.
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PROFORMA FOR THERAPEUTIC TRAIL FOR ALOPECIA AREATA
Case No.
OP NO:
Name 
Address
Age/Sex
Occupation
Complaints
i. Loss of hair – Duration
ii. Pruritus
iii. Others ( specify)
Treatment taken in the past
a) Topical application 
                                                      Duration 
Clinical response
1) Steroids preparation
2) Others ( specify)
3) Native medicine
b) Systemic therapy 
1) Oral steroids
2) Others ( specify)
c) Other modes of treatment ( specify)
Family history 
Diabetes mellitus
Hypertension
Atopy ( specify the features)
Endocrine disorders
Autoimmune disorders
Personal history
Hypertension
Diabetes mellitus
Migrane
Urticaria
Childhood eczema
Thyroid disease
Septic foci – ENT/DENTAL/OTHERS ( specify)
Past history of the same disease
Site 
Duration
No. of episodes
Duration of treatment
Response of treatment
General examination
Pallor
Icterus
Lymphadenopathy
BP
Systemic examination
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Cardiovascular system
Respiratory system
ENT
DENTAL
Other finding if any
Dermatological examination
No of patches
Site Size Shape Presence of 
white hair
Coudability sign
Exclamation hair mark
Nail changes – Pitting, others ( specify)
Associated changes – Vitiligo, Other dermatosis (specify)
Oral mucosa
Palms and soles
Eyes
Investigations
Blood sugar
Other investigation ( specify)
THERAPY - GIVEN 
Duration of therapy
Post therapeutic follow up
Clinical 
response
2nd 
week
4th 
wee
k
6th 
week 
8th 
week 
10th 
week
12th 
week
14th 
week
16th 
wee
k
Patch size
Hair 
growth
Pigmentati
on
Length of 
hair
Adverse 
effects
2nd 
wee
k
4th 
week
6th 
week 
8th 
week 
10th 
wee
k
12th 
wee
k
14th 
week
16th 
week
Pigmentation
Irritant 
reaction
Burning
Itching
Folliculitis
108
Others 
( specify)
Result:
Pre treatment and post treatment photographs
LEGENDS
AA – Alopecia areata
B – Beard
DC – Dental caries
EB – Eyebrows
F – Frontal
G – Chronic gingivitis
HPO – Hyperpigmentation of oral mucosa
HT – Hyperthyroidism
Lt – Left
L – Leuconychia
LP – Lichen planus
LS – Longitudinal striations
M – Melanonychia
O – Oophiasis
OSF – Oral submucosal fibrosis
P – Parietal
PCOD – Polycystic ovarian disease
RHD – Rheumatic heart disease
R – Right
Seb.derm – Seborrheic dermatitis
TC – Tinea cruris/ Tinea corporis
V – Vertex
VVC – Vulvovaginal candidosis
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